Current indications and possibilities of immunooncological treatment

05/2020

MUDr. Libor Havel

Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

SUMMARY

Immunotherapy in the form of immune checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4 has become an integral part of lung cancer treatment algorithms. The dynamics of progress in this field can undoubtedly be called unbelievable. In the conditions of the Czech Republic, there is a certain delay towards the world in the availability of individual treatments. However, there are a number of patients who intend to make the most of all available treatment options, even if they are not covered by general health insurance. The following text is therefore conceived as an overview of available and in some parts of the world registered treatment methods, not what is currently covered in the Czech Republic by health insurance.

Key words

immunotherapy, immune checkpoint inhibitors, PD-1/PD-L1, CTLA-4, lung cancer